SLC5A2 and diabetes mellitus: Therefore, it is highly recommended that information on the presence and degree of DR should be incorporated in the randomization process of patients with DM for any future studies with GLP-1 RAs and SGLT-2 inhibitors, regardless of outcomes the studies are aimed at.